EHMT2 and neoplasm: By chemically inhibiting G9a/GLP, the researchers successfully generated functionally mature CAR‐T cells from human iPSCs, presenting a novel strategy for off‐the‐shelf immunotherapy.[134] While these CAR iPSC‐T cells demonstrated enhanced anti‐tumor activity both in vitro and in vivo—particularly in tumor rechallenge models where they exhibited persistent tumor clearance and therapeutic potential—challenges remain.